Tags : Semaglutide

Novo Nordisk Files MAA for Semaglutide to the EMA for

Shots: The submission is based on 10 PIONEER studies assessing semaglutide vs sitagliptin, empagliflozin, liraglutide and dulaglutide in 9,543 adult patients with type 2 diabetes The collective studies result demonstrated reduction in HbA1c and weight loss with safe & well tolerated data Semaglutide (qd) is an oral GLP-1 receptor agonist administered once-daily with its expected […]Read More